Jerusalem Venture Partners (JVP)

Jeito Capital is a Paris-based healthcare-focused growth equity firm founded in 2020, established as one of the first pan-European healthcare-dedicated growth equity platforms to raise institutional capital at scale for European clinical-stage and commercial-stage healthcare companies. The firm manages more than $600 million in committed capital and invests at Series B and growth stages with initial checks from $10 million to $50 million in biopharmaceutical, medical device, and health technology companies across Europe and North America developing breakthrough treatments for serious diseases. Jeito brings operational expertise in clinical development, regulatory strategy, and pharmaceutical commercialisation alongside the capital. Portfolio companies include Acticor Biotech, the French clinical-stage biotech developing anti-thrombosis treatments; Aminofix, a medical company focused on amino acid therapeutics; Carmat, the French medical device company developing an artificial heart for end-stage heart failure patients; and Xentech, the French patient-derived xenograft platform for oncology drug development. Beyond its original investments, the portfolio includes additional European clinical-stage biopharmaceutical and medical technology companies.